ArticleJournal of proteome research2026
Mapping of the hSOX10 Proximal Protein Interactome in Human Melanoma.
Article in Journal of proteome research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The transcription factor SOX10 is a central regulator of melanoma, influencing tumor initiation, progression, phenotypic plasticity, and therapeutic resistance, yet the protein-protein interactions underlying its function remain poorly defined. To address this, we conducted the first dedicated, comprehensive mapping of the human SOX10 (hSOX10) proximal protein interactome using miniTurbo (mT) proximity-dependent biotinylation coupled with mass spectrometry in A375 melanoma cells. Stable lines expressing N- or C-terminal mT-tagged hSOX10 fusion proteins at near-endogenous levels enabled the unbiased capture of proximal proteins in a native cellular context, identifying 847 melanoma-enriched candidate hSOX10 interactors. Stringent statistical filtering, contaminant frequency profiling, and subcellular localization context refined this to 180 high-confidence candidates, including known hSOX10 partners and previously unidentified candidates. Integration of orthogonal biological relevance criteria (functional enrichment and network context, transcriptomic coexpression with hSOX10, and genomic co-occurrence in melanoma) further refined the dataset to 124 biologically relevant candidates enriched for transcriptional regulators, cofactors, chromatin-modifying complexes, and associated pathways. These proteins were stratified using an evidence-based prioritization framework incorporating transcriptomic, genomic, and chromatin-based context without additional exclusion. Collectively, this work provides a high-confidence resource for the hSOX10 proximal protein interactome in melanoma and a framework for generating testable hypotheses regarding hSOX10-associated regulatory networks, melanoma biology, and therapeutic vulnerabilities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.